Cat. No.: 
Price $295.00
100 µg

Cell Lysate isolated from MDA231-DOX[r] cell line.

MDA231-DOX[r] cells are 2.7-fold more resistant to inhibition by DOXORUBICIN than parental MDA-MB-231 cells. DOXORUBICIN IC50s for MDA231-DOX[r] and parental MDA-MB-231 cells are 7.4 nM and 2.8 nM, respectively (MTT assay). MDA231-DOX[r] cells were established following 6 months of continuous in vitro exposure of parental MDA-MB-231 cells to DOXORUBICIN.

Cell Line: MDA-MB-231 was established from a pleural effusion of a 51 year old caucasian woman with metastatic breast cancer (Cailleau R et al, 1974). The tumor origin is considered an invasive ductal adenocarcinoma, basal-B subtype, with a subset of cells expressing a mesenchymal-like phenotype.

Parent phenotype: Triple negative (ERα, PR-, normal HER-2), EGFR+; CD44+/CD 24-/ESA+ (40% population, tumor-initiating cells).

Compound: DOXORUBICIN (Adriamycin) interacts with DNA by intercalation and inhibits the progression of topoisomerase II, which relaxes supercoils in DNA for transcription. DOXORUBICIN also induces histone eviction from chromatin thereby attenuating DNA repair. DOXORUBICIN is used to treat early-stage or node-positive breast cancer, HER2-positive breast cancer, and metastatic disease.